-
EP3119406
European procedure
Extract from the Register of European Patents
EP About this file: EP3119406
| EP3119406 - METHODS FOR IMPROVING COGNITIVE FUNCTION VIA MODULATION OF QUINONE REDUCTASE 2 [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 26.11.2021 Database last updated on 20.07.2024 | |
| Former | The patent has been granted Status updated on 18.12.2020 | ||
| Former | Grant of patent is intended Status updated on 11.08.2020 | ||
| Former | Examination is in progress Status updated on 12.04.2019 | ||
| Former | Request for examination was made Status updated on 23.12.2016 | ||
| Former | The international publication has been made Status updated on 16.11.2016 | Most recent event Tooltip | 14.06.2024 | Lapse of the patent in a contracting state New state(s): TR | published on 17.07.2024 [2024/29] | Applicant(s) | For all designated states Carmel-Haifa University Economic Corporation Ltd Eshkol Tower, University of Haifa Mount Carmel 3498838 Haifa / IL | [2017/04] | Inventor(s) | 01 /
ROSENBLUM, Kobi c/o Carmel-Haifa University Economic Corp. Ltd Eshkol Tower Haifa University Mount Carmel 3498838 Haifa / IL | 02 /
RAPPAPORT, Akiva c/o Carmel-Haifa University Economic Corp. Ltd Eshkol Tower Haifa University Mount Carmel 3498838 Haifa / IL | [2017/04] | Representative(s) | Balder IP Law, S.L. Paseo de la Castellana 93 5ª planta 28046 Madrid / ES | [2021/03] |
| Former [2017/04] | Balder IP Law, S.L. Castellana 93 28046 Madrid / ES | Application number, filing date | 15764336.2 | 18.03.2015 | [2017/04] | WO2015IL50284 | Priority number, date | US201461954687P | 18.03.2014 Original published format: US 201461954687 P | [2017/04] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2015140799 | Date: | 24.09.2015 | Language: | EN | [2015/38] | Type: | A1 Application with search report | No.: | EP3119406 | Date: | 25.01.2017 | Language: | EN | The application published by WIPO in one of the EPO official languages on 24.09.2015 takes the place of the publication of the European patent application. | [2017/04] | Type: | B1 Patent specification | No.: | EP3119406 | Date: | 20.01.2021 | Language: | EN | [2021/03] | Search report(s) | International search report - published on: | IL | 24.09.2015 | (Supplementary) European search report - dispatched on: | EP | 10.11.2017 | Classification | IPC: | A61K31/713, A61K31/7105, A61K48/00, A61K31/05, A61P25/28, A61K31/352, A61K31/10, A61K31/136, A61K31/407 | [2017/04] | CPC: |
C12N15/1137 (EP,US);
A61K31/05 (IL);
A61K31/10 (IL);
A61K31/136 (IL);
A61K31/165 (EP,IL,US);
A61K31/255 (EP,US);
A61K31/352 (IL);
A61K31/404 (EP,IL,US);
A61K31/4045 (EP,IL,US);
A61K31/407 (IL);
A61K31/4375 (EP,IL,US);
A61K31/455 (EP,IL,US);
A61K31/7064 (EP,IL,US);
A61K31/7105 (EP,IL,US);
A61K31/713 (EP,IL,US);
A61K48/00 (IL);
A61P25/28 (EP);
C12Y106/05005 (EP,US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2017/04] | Extension states | BA | Not yet paid | ME | Not yet paid | Validation states | MA | Not yet paid | Title | German: | VERFAHREN ZUR VERBESSERUNG DER KOGNITIVEN FUNKTION DURCH MODULATION VON CHINON-REDUKTASE 2 | [2017/04] | English: | METHODS FOR IMPROVING COGNITIVE FUNCTION VIA MODULATION OF QUINONE REDUCTASE 2 | [2017/04] | French: | PROCÉDÉS POUR AMÉLIORER LA FONCTION COGNITIVE PAR L'INTERMÉDIAIRE DE LA MODULATION DE L'ACTIVITÉ DE LA QUINONE RÉDUCTASE 2 | [2017/04] | Entry into regional phase | 13.10.2016 | National basic fee paid | 13.10.2016 | Search fee paid | 13.10.2016 | Designation fee(s) paid | 13.10.2016 | Examination fee paid | Examination procedure | 13.10.2016 | Examination requested [2017/04] | 13.10.2016 | Date on which the examining division has become responsible | 22.05.2018 | Amendment by applicant (claims and/or description) | 16.04.2019 | Despatch of a communication from the examining division (Time limit: M04) | 14.08.2019 | Reply to a communication from the examining division | 19.12.2019 | Despatch of a communication from the examining division (Time limit: M04) | 21.04.2020 | Reply to a communication from the examining division | 12.08.2020 | Communication of intention to grant the patent | 09.12.2020 | Fee for grant paid | 09.12.2020 | Fee for publishing/printing paid | 09.12.2020 | Receipt of the translation of the claim(s) | Opposition(s) | 21.10.2021 | No opposition filed within time limit [2021/52] | Fees paid | Renewal fee | 24.03.2017 | Renewal fee patent year 03 | 23.03.2018 | Renewal fee patent year 04 | 26.03.2019 | Renewal fee patent year 05 | 24.03.2020 | Renewal fee patent year 06 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | HU | 18.03.2015 | AL | 20.01.2021 | AT | 20.01.2021 | CY | 20.01.2021 | CZ | 20.01.2021 | DK | 20.01.2021 | EE | 20.01.2021 | ES | 20.01.2021 | FI | 20.01.2021 | HR | 20.01.2021 | IT | 20.01.2021 | LT | 20.01.2021 | LV | 20.01.2021 | MC | 20.01.2021 | MK | 20.01.2021 | NL | 20.01.2021 | PL | 20.01.2021 | RO | 20.01.2021 | RS | 20.01.2021 | SE | 20.01.2021 | SI | 20.01.2021 | SK | 20.01.2021 | SM | 20.01.2021 | TR | 20.01.2021 | IE | 18.03.2021 | LU | 18.03.2021 | BE | 31.03.2021 | CH | 31.03.2021 | LI | 31.03.2021 | BG | 20.04.2021 | NO | 20.04.2021 | GR | 21.04.2021 | IS | 20.05.2021 | PT | 20.05.2021 | [2024/29] |
| Former [2024/22] | HU | 18.03.2015 | |
| AL | 20.01.2021 | ||
| AT | 20.01.2021 | ||
| CY | 20.01.2021 | ||
| CZ | 20.01.2021 | ||
| DK | 20.01.2021 | ||
| EE | 20.01.2021 | ||
| ES | 20.01.2021 | ||
| FI | 20.01.2021 | ||
| HR | 20.01.2021 | ||
| IT | 20.01.2021 | ||
| LT | 20.01.2021 | ||
| LV | 20.01.2021 | ||
| MC | 20.01.2021 | ||
| MK | 20.01.2021 | ||
| NL | 20.01.2021 | ||
| PL | 20.01.2021 | ||
| RO | 20.01.2021 | ||
| RS | 20.01.2021 | ||
| SE | 20.01.2021 | ||
| SI | 20.01.2021 | ||
| SK | 20.01.2021 | ||
| SM | 20.01.2021 | ||
| IE | 18.03.2021 | ||
| LU | 18.03.2021 | ||
| BE | 31.03.2021 | ||
| CH | 31.03.2021 | ||
| LI | 31.03.2021 | ||
| BG | 20.04.2021 | ||
| NO | 20.04.2021 | ||
| GR | 21.04.2021 | ||
| IS | 20.05.2021 | ||
| PT | 20.05.2021 | ||
| Former [2023/30] | HU | 18.03.2015 | |
| AL | 20.01.2021 | ||
| AT | 20.01.2021 | ||
| CY | 20.01.2021 | ||
| CZ | 20.01.2021 | ||
| DK | 20.01.2021 | ||
| EE | 20.01.2021 | ||
| ES | 20.01.2021 | ||
| FI | 20.01.2021 | ||
| HR | 20.01.2021 | ||
| IT | 20.01.2021 | ||
| LT | 20.01.2021 | ||
| LV | 20.01.2021 | ||
| MC | 20.01.2021 | ||
| NL | 20.01.2021 | ||
| PL | 20.01.2021 | ||
| RO | 20.01.2021 | ||
| RS | 20.01.2021 | ||
| SE | 20.01.2021 | ||
| SI | 20.01.2021 | ||
| SK | 20.01.2021 | ||
| SM | 20.01.2021 | ||
| IE | 18.03.2021 | ||
| LU | 18.03.2021 | ||
| BE | 31.03.2021 | ||
| CH | 31.03.2021 | ||
| LI | 31.03.2021 | ||
| BG | 20.04.2021 | ||
| NO | 20.04.2021 | ||
| GR | 21.04.2021 | ||
| IS | 20.05.2021 | ||
| PT | 20.05.2021 | ||
| Former [2023/27] | HU | 18.03.2015 | |
| AL | 20.01.2021 | ||
| AT | 20.01.2021 | ||
| CZ | 20.01.2021 | ||
| DK | 20.01.2021 | ||
| EE | 20.01.2021 | ||
| ES | 20.01.2021 | ||
| FI | 20.01.2021 | ||
| HR | 20.01.2021 | ||
| IT | 20.01.2021 | ||
| LT | 20.01.2021 | ||
| LV | 20.01.2021 | ||
| MC | 20.01.2021 | ||
| NL | 20.01.2021 | ||
| PL | 20.01.2021 | ||
| RO | 20.01.2021 | ||
| RS | 20.01.2021 | ||
| SE | 20.01.2021 | ||
| SI | 20.01.2021 | ||
| SK | 20.01.2021 | ||
| SM | 20.01.2021 | ||
| IE | 18.03.2021 | ||
| LU | 18.03.2021 | ||
| BE | 31.03.2021 | ||
| CH | 31.03.2021 | ||
| LI | 31.03.2021 | ||
| BG | 20.04.2021 | ||
| NO | 20.04.2021 | ||
| GR | 21.04.2021 | ||
| IS | 20.05.2021 | ||
| PT | 20.05.2021 | ||
| Former [2022/34] | AL | 20.01.2021 | |
| AT | 20.01.2021 | ||
| CZ | 20.01.2021 | ||
| DK | 20.01.2021 | ||
| EE | 20.01.2021 | ||
| ES | 20.01.2021 | ||
| FI | 20.01.2021 | ||
| HR | 20.01.2021 | ||
| IT | 20.01.2021 | ||
| LT | 20.01.2021 | ||
| LV | 20.01.2021 | ||
| MC | 20.01.2021 | ||
| NL | 20.01.2021 | ||
| PL | 20.01.2021 | ||
| RO | 20.01.2021 | ||
| RS | 20.01.2021 | ||
| SE | 20.01.2021 | ||
| SI | 20.01.2021 | ||
| SK | 20.01.2021 | ||
| SM | 20.01.2021 | ||
| IE | 18.03.2021 | ||
| LU | 18.03.2021 | ||
| BE | 31.03.2021 | ||
| CH | 31.03.2021 | ||
| LI | 31.03.2021 | ||
| BG | 20.04.2021 | ||
| NO | 20.04.2021 | ||
| GR | 21.04.2021 | ||
| IS | 20.05.2021 | ||
| PT | 20.05.2021 | ||
| Former [2022/23] | AL | 20.01.2021 | |
| AT | 20.01.2021 | ||
| CZ | 20.01.2021 | ||
| DK | 20.01.2021 | ||
| EE | 20.01.2021 | ||
| ES | 20.01.2021 | ||
| FI | 20.01.2021 | ||
| HR | 20.01.2021 | ||
| IT | 20.01.2021 | ||
| LT | 20.01.2021 | ||
| LV | 20.01.2021 | ||
| MC | 20.01.2021 | ||
| NL | 20.01.2021 | ||
| PL | 20.01.2021 | ||
| RO | 20.01.2021 | ||
| RS | 20.01.2021 | ||
| SE | 20.01.2021 | ||
| SI | 20.01.2021 | ||
| SK | 20.01.2021 | ||
| SM | 20.01.2021 | ||
| IE | 18.03.2021 | ||
| LU | 18.03.2021 | ||
| CH | 31.03.2021 | ||
| LI | 31.03.2021 | ||
| BG | 20.04.2021 | ||
| NO | 20.04.2021 | ||
| GR | 21.04.2021 | ||
| IS | 20.05.2021 | ||
| PT | 20.05.2021 | ||
| Former [2022/11] | AL | 20.01.2021 | |
| AT | 20.01.2021 | ||
| CZ | 20.01.2021 | ||
| DK | 20.01.2021 | ||
| EE | 20.01.2021 | ||
| ES | 20.01.2021 | ||
| FI | 20.01.2021 | ||
| HR | 20.01.2021 | ||
| LT | 20.01.2021 | ||
| LV | 20.01.2021 | ||
| MC | 20.01.2021 | ||
| NL | 20.01.2021 | ||
| PL | 20.01.2021 | ||
| RO | 20.01.2021 | ||
| RS | 20.01.2021 | ||
| SE | 20.01.2021 | ||
| SI | 20.01.2021 | ||
| SK | 20.01.2021 | ||
| SM | 20.01.2021 | ||
| IE | 18.03.2021 | ||
| LU | 18.03.2021 | ||
| CH | 31.03.2021 | ||
| LI | 31.03.2021 | ||
| BG | 20.04.2021 | ||
| NO | 20.04.2021 | ||
| GR | 21.04.2021 | ||
| PT | 20.05.2021 | ||
| Former [2022/10] | AL | 20.01.2021 | |
| AT | 20.01.2021 | ||
| CZ | 20.01.2021 | ||
| DK | 20.01.2021 | ||
| EE | 20.01.2021 | ||
| ES | 20.01.2021 | ||
| FI | 20.01.2021 | ||
| HR | 20.01.2021 | ||
| LT | 20.01.2021 | ||
| LV | 20.01.2021 | ||
| MC | 20.01.2021 | ||
| NL | 20.01.2021 | ||
| PL | 20.01.2021 | ||
| RO | 20.01.2021 | ||
| RS | 20.01.2021 | ||
| SE | 20.01.2021 | ||
| SK | 20.01.2021 | ||
| SM | 20.01.2021 | ||
| IE | 18.03.2021 | ||
| LU | 18.03.2021 | ||
| CH | 31.03.2021 | ||
| LI | 31.03.2021 | ||
| BG | 20.04.2021 | ||
| NO | 20.04.2021 | ||
| GR | 21.04.2021 | ||
| PT | 20.05.2021 | ||
| Former [2022/09] | AL | 20.01.2021 | |
| AT | 20.01.2021 | ||
| CZ | 20.01.2021 | ||
| DK | 20.01.2021 | ||
| EE | 20.01.2021 | ||
| ES | 20.01.2021 | ||
| FI | 20.01.2021 | ||
| HR | 20.01.2021 | ||
| LT | 20.01.2021 | ||
| LV | 20.01.2021 | ||
| MC | 20.01.2021 | ||
| NL | 20.01.2021 | ||
| PL | 20.01.2021 | ||
| RO | 20.01.2021 | ||
| RS | 20.01.2021 | ||
| SE | 20.01.2021 | ||
| SK | 20.01.2021 | ||
| SM | 20.01.2021 | ||
| IE | 18.03.2021 | ||
| LU | 18.03.2021 | ||
| BG | 20.04.2021 | ||
| NO | 20.04.2021 | ||
| GR | 21.04.2021 | ||
| IS | 20.05.2021 | ||
| PT | 20.05.2021 | ||
| Former [2022/07] | AL | 20.01.2021 | |
| AT | 20.01.2021 | ||
| CZ | 20.01.2021 | ||
| DK | 20.01.2021 | ||
| EE | 20.01.2021 | ||
| ES | 20.01.2021 | ||
| FI | 20.01.2021 | ||
| HR | 20.01.2021 | ||
| LT | 20.01.2021 | ||
| LV | 20.01.2021 | ||
| MC | 20.01.2021 | ||
| NL | 20.01.2021 | ||
| PL | 20.01.2021 | ||
| RO | 20.01.2021 | ||
| RS | 20.01.2021 | ||
| SE | 20.01.2021 | ||
| SK | 20.01.2021 | ||
| SM | 20.01.2021 | ||
| IE | 18.03.2021 | ||
| BG | 20.04.2021 | ||
| NO | 20.04.2021 | ||
| GR | 21.04.2021 | ||
| IS | 20.05.2021 | ||
| PT | 20.05.2021 | ||
| Former [2021/51] | AT | 20.01.2021 | |
| CZ | 20.01.2021 | ||
| DK | 20.01.2021 | ||
| EE | 20.01.2021 | ||
| ES | 20.01.2021 | ||
| FI | 20.01.2021 | ||
| HR | 20.01.2021 | ||
| LT | 20.01.2021 | ||
| LV | 20.01.2021 | ||
| MC | 20.01.2021 | ||
| NL | 20.01.2021 | ||
| PL | 20.01.2021 | ||
| RO | 20.01.2021 | ||
| RS | 20.01.2021 | ||
| SE | 20.01.2021 | ||
| SK | 20.01.2021 | ||
| SM | 20.01.2021 | ||
| BG | 20.04.2021 | ||
| NO | 20.04.2021 | ||
| GR | 21.04.2021 | ||
| IS | 20.05.2021 | ||
| PT | 20.05.2021 | ||
| Former [2021/50] | AT | 20.01.2021 | |
| CZ | 20.01.2021 | ||
| DK | 20.01.2021 | ||
| EE | 20.01.2021 | ||
| FI | 20.01.2021 | ||
| HR | 20.01.2021 | ||
| LT | 20.01.2021 | ||
| LV | 20.01.2021 | ||
| MC | 20.01.2021 | ||
| NL | 20.01.2021 | ||
| PL | 20.01.2021 | ||
| RO | 20.01.2021 | ||
| RS | 20.01.2021 | ||
| SE | 20.01.2021 | ||
| SK | 20.01.2021 | ||
| SM | 20.01.2021 | ||
| BG | 20.04.2021 | ||
| NO | 20.04.2021 | ||
| GR | 21.04.2021 | ||
| IS | 20.05.2021 | ||
| PT | 20.05.2021 | ||
| Former [2021/49] | AT | 20.01.2021 | |
| CZ | 20.01.2021 | ||
| DK | 20.01.2021 | ||
| EE | 20.01.2021 | ||
| FI | 20.01.2021 | ||
| HR | 20.01.2021 | ||
| LT | 20.01.2021 | ||
| LV | 20.01.2021 | ||
| MC | 20.01.2021 | ||
| NL | 20.01.2021 | ||
| PL | 20.01.2021 | ||
| RS | 20.01.2021 | ||
| SE | 20.01.2021 | ||
| SM | 20.01.2021 | ||
| BG | 20.04.2021 | ||
| NO | 20.04.2021 | ||
| GR | 21.04.2021 | ||
| IS | 20.05.2021 | ||
| PT | 20.05.2021 | ||
| Former [2021/48] | AT | 20.01.2021 | |
| CZ | 20.01.2021 | ||
| EE | 20.01.2021 | ||
| FI | 20.01.2021 | ||
| HR | 20.01.2021 | ||
| LT | 20.01.2021 | ||
| LV | 20.01.2021 | ||
| MC | 20.01.2021 | ||
| NL | 20.01.2021 | ||
| PL | 20.01.2021 | ||
| RS | 20.01.2021 | ||
| SE | 20.01.2021 | ||
| SM | 20.01.2021 | ||
| BG | 20.04.2021 | ||
| NO | 20.04.2021 | ||
| GR | 21.04.2021 | ||
| IS | 20.05.2021 | ||
| PT | 20.05.2021 | ||
| Former [2021/46] | AT | 20.01.2021 | |
| FI | 20.01.2021 | ||
| HR | 20.01.2021 | ||
| LT | 20.01.2021 | ||
| LV | 20.01.2021 | ||
| MC | 20.01.2021 | ||
| NL | 20.01.2021 | ||
| PL | 20.01.2021 | ||
| RS | 20.01.2021 | ||
| SE | 20.01.2021 | ||
| SM | 20.01.2021 | ||
| BG | 20.04.2021 | ||
| NO | 20.04.2021 | ||
| GR | 21.04.2021 | ||
| IS | 20.05.2021 | ||
| PT | 20.05.2021 | ||
| Former [2021/45] | AT | 20.01.2021 | |
| FI | 20.01.2021 | ||
| HR | 20.01.2021 | ||
| LT | 20.01.2021 | ||
| LV | 20.01.2021 | ||
| MC | 20.01.2021 | ||
| NL | 20.01.2021 | ||
| PL | 20.01.2021 | ||
| RS | 20.01.2021 | ||
| SE | 20.01.2021 | ||
| BG | 20.04.2021 | ||
| NO | 20.04.2021 | ||
| GR | 21.04.2021 | ||
| IS | 20.05.2021 | ||
| PT | 20.05.2021 | ||
| Former [2021/42] | AT | 20.01.2021 | |
| FI | 20.01.2021 | ||
| HR | 20.01.2021 | ||
| LT | 20.01.2021 | ||
| LV | 20.01.2021 | ||
| NL | 20.01.2021 | ||
| PL | 20.01.2021 | ||
| RS | 20.01.2021 | ||
| SE | 20.01.2021 | ||
| BG | 20.04.2021 | ||
| NO | 20.04.2021 | ||
| GR | 21.04.2021 | ||
| IS | 20.05.2021 | ||
| PT | 20.05.2021 | ||
| Former [2021/39] | AT | 20.01.2021 | |
| FI | 20.01.2021 | ||
| HR | 20.01.2021 | ||
| LT | 20.01.2021 | ||
| LV | 20.01.2021 | ||
| NL | 20.01.2021 | ||
| PL | 20.01.2021 | ||
| RS | 20.01.2021 | ||
| SE | 20.01.2021 | ||
| BG | 20.04.2021 | ||
| NO | 20.04.2021 | ||
| GR | 21.04.2021 | ||
| PT | 20.05.2021 | ||
| Former [2021/38] | AT | 20.01.2021 | |
| FI | 20.01.2021 | ||
| HR | 20.01.2021 | ||
| LT | 20.01.2021 | ||
| LV | 20.01.2021 | ||
| NL | 20.01.2021 | ||
| RS | 20.01.2021 | ||
| SE | 20.01.2021 | ||
| BG | 20.04.2021 | ||
| NO | 20.04.2021 | ||
| GR | 21.04.2021 | ||
| PT | 20.05.2021 | ||
| Former [2021/37] | AT | 20.01.2021 | |
| FI | 20.01.2021 | ||
| HR | 20.01.2021 | ||
| LT | 20.01.2021 | ||
| LV | 20.01.2021 | ||
| NL | 20.01.2021 | ||
| RS | 20.01.2021 | ||
| BG | 20.04.2021 | ||
| NO | 20.04.2021 | ||
| GR | 21.04.2021 | ||
| PT | 20.05.2021 | ||
| Former [2021/36] | FI | 20.01.2021 | |
| HR | 20.01.2021 | ||
| LT | 20.01.2021 | ||
| NL | 20.01.2021 | ||
| BG | 20.04.2021 | ||
| NO | 20.04.2021 | ||
| GR | 21.04.2021 | ||
| PT | 20.05.2021 | ||
| Former [2021/35] | FI | 20.01.2021 | |
| HR | 20.01.2021 | ||
| LT | 20.01.2021 | ||
| NL | 20.01.2021 | ||
| NO | 20.04.2021 | ||
| PT | 20.05.2021 | ||
| Former [2021/34] | FI | 20.01.2021 | |
| LT | 20.01.2021 | ||
| NL | 20.01.2021 | ||
| NO | 20.04.2021 | ||
| PT | 20.05.2021 | ||
| Former [2021/33] | FI | 20.01.2021 | |
| LT | 20.01.2021 | ||
| NO | 20.04.2021 | ||
| PT | 20.05.2021 | Documents cited: | Search | [I]WO2008144455 (HELICON THERAPEUTICS INC [US], et al) [I] 1-12 *cf. abstract, page 3, lines 1-5, claims 1, 6, 26 and 35*; | [Y] - ANTOINE M ET AL, "Characterization of cofactors, substrates and inhibitor binding to flavoenzyme quinone reductase 2 by automated supramolecular nano-electrospray ionization mass spectrometry", INSPEC, THE INSTITUTION OF ELECTRICAL ENGINEERS, STEVENAGE, GB, (20120215), Database accession no. 13163738, XP002774960 [Y] 1-12 * abstract * DOI: http://dx.doi.org/10.1016/j.ijms.2011.07.011 | [Y] - CAI JING-BO ET AL, "NEGATIVE REGULATION OF QUINONE REDUCTASE 2 BY RESVERATROL IN CULTURED VASCULAR SMOOTH MUSCLE CELLS", vol. 35, no. 12, doi:10.1111/J.1440-1681.2008.05006.X, ISSN 0305-1870, (20081201), pages 1419 - 1425, CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, WILEY-BLACKWELL PUBLISHING ASIA, AU, URL: http://epo.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV07b9swECbaTl36SIrUaQtwKDJFqB4kZY2qLDsGFMnVw0AmQqKpLEkQxCkQ__veUawVAx2KoppOL0KiPt6DuvtIyFeP-S3vW-V4QccdpoLWiXg_dVq28cE9Epr1WI18lbB6EZYLlo3l0QM9xH6-DQeGUdfPxvf-h6SYejYXkuMvhadvbYezA-oRFDJaRQD3is3GfA-7rFqA1JuA0sO0nj-2eGCrrMYea572FsuU3h86t8Y6, XP009500819 [Y] 1-12 *cf. summary* DOI: http://dx.doi.org/10.1111/j.1440-1681.2008.05006.x | [Y] - BURYANOVSKYY LEONID ET AL, "Crystal structure of quinone reductase 2 in complex with resveratrol", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, (20040914), vol. 43, no. 36, doi:10.1021/BI049162O, ISSN 0006-2960, pages 11417 - 11426, XP009500820 [Y] 1-12 *cf. abstract, right-hand col. at page 11424* DOI: http://dx.doi.org/10.1021/bi049162o | [Y] - CHOMARAT ET AL, "Cellular knock-down of quinone reductase 2: A laborious road to successful inhibition by RNA interference", BIOCHIMIE, MASSON, PARIS, FR, (20071001), vol. 89, no. 10, doi:10.1016/J.BIOCHI.2007.07.004, ISSN 0300-9084, pages 1264 - 1275, XP022323805 [Y] 1-12 *cf. abstract* DOI: http://dx.doi.org/10.1016/j.biochi.2007.07.004 | International search | [X]WO0238141 (MASSACHUSETTS INST TECHNOLOGY [US], et al) [X] 1, 7-13, 15-17, 23-26, 29 * examples, claims *; | [X]WO2008013764 (TOPPO FRANK [US], et al) [X] 1, 7-13, 15-17, 23-26, 29 * examples, claims *; | [X] - BENOIT, CHARLES-ETIENNE et al., "Loss of quinone reductase 2 function selectively facilitates learning behaviors.", The Journal of Neuroscience, vol. 30, no. 38, ISSN 0270-6474, (20100922), pages 12690 - 12700., URL: http://www.jneurosci.org/content/30/38/12690.full, XP055225330 [X] 1-31 * Figs 4-5 * DOI: http://dx.doi.org/10.1523/JNEUROSCI.2808-10.2010 | [X] - WU, YUANYUAN., "Neuroprotective effects of lithium on scopolamine-induced amnesia through decreasing quinone reductase 2 in rats.", Alzheimer's & Dementia, vol. 8.4, (20120731), pages 199 - 200., URL: http://www.alzheimersanddementia.com/article/S1552-5260(12)00678-4/fulltext [X] 131 * abstract * | [PX] - FITZPATRICK, JESSE et al., "Inhibition Of Quinone Oxidoreductase 2 Improves Learning In A Mouse Model Of Vascular Dementia (P1. 237).", Neurology, vol. 82.10, (20140428), pages 1 - 237, URL: http://www.neurology.org/content/82/10_Supplement/P1.237, XP055358453 [PX] 1-31 * abstract * | [A] - HASHIMOTO, TETSUYA; et al., "Increased hippocampal quinone reductase 2 in Alzheimer's disease.", Neuroscience letters, (20110908), vol. 502.1, pages 10 - 12, XP028383453 [A] 1-31 * the whole document * DOI: http://dx.doi.org/10.1016/j.neulet.2011.07.008 | by applicant | US6610287 | US7749973 | US2013287736 | - BENOIT et al., "Loss of quinone reductase 2 function selectively facilitates learning behaviors.", The Journal ofNeuroscience, (20100922), vol. 30, no. 38, doi:doi:10.1523/JNEUROSCI.2808-10.2010, ISSN 0270-6474, pages 12690 - 12700, XP055225330 DOI: http://dx.doi.org/10.1523/JNEUROSCI.2808-10.2010 | - HASHIMOTO et al., "Increased hippocampal quinone reductase 2 in Alzheimer's disease", Neuroscience letters, (20110908), vol. 502, no. 1, doi:doi:10.1016/j.neulet.2011.07.008, pages 10 - 12, XP028383453 DOI: http://dx.doi.org/10.1016/j.neulet.2011.07.008 | - BAILEY, C. H.D. BARTSCHE. R. KANDEL, "Toward a Molecular Definition of Long-term Memory Storage", Proc Natl Acad Sci USA, vol. 93.24, (19960000), pages 13445 - 3452, URL: 13445-3452 | - BENOIT, C.-E.S. BASTIANETTOJ. BROUILLETTEY. TSEJ. A. BOUTINP. DELAGRANGET. WONGP. SARRETR. QUIRION, "Loss of Quinone Reductase 2 Function Selectively Facilitates Learning Behaviors", Journal of Neuroscience, (20100000), vol. 30.38, doi:doi:10.1523/JNEUROSCI.2808-10.2010, pages 12690 - 2700, XP055225330 DOI: http://dx.doi.org/10.1523/JNEUROSCI.2808-10.2010 | - BROUILLETTEJONATHANREMI QUIRION, "Transthyretin: A Key Gene Involved in the Maintenance of Memory Capacities during Aging", Neurobiology of Aging, (20080000), vol. 29.11, doi:doi:10.1016/j.neurobiolaging.2007.04.007, pages 1721 - 732, XP025428366 DOI: http://dx.doi.org/10.1016/j.neurobiolaging.2007.04.007 | - BROUILLETTE, J.D. YOUNGM. DURINGR. QUIRION, "Hippocampal Gene Expression Profiling Reveals the Possible Involvement of Homerl and GABAB Receptors in Scopolamine-induced Amnesia", JNeurochemistry, (20070000), vol. 102.6, pages 1978 - 989 | - MEIRINOAMKOBI ROSENBLUM, "Lateral Ventricle Injection of the Protein Synthesis Inhibitor Anisomycin Impairs Long-term Memory in a Spatial Memory Task", Brain Research, (19980000), vol. 789.1, pages 48 - 55 | - BURYANOVSKYYLEONIDYUE FUMOLLY BOYDYULIANG MATZE-CHEN HSIEHJOSEPH M. WUZHONGTAO ZHANG, "Crystal Structure of Quinone Reductase 2 in Complex with Resveratrol", Biochemistry, (20040000), vol. 43.36, doi:doi:10.1021/bi049162o, pages 11417 - 1426, XP009500820 DOI: http://dx.doi.org/10.1021/bi049162o | - FERRYGILLESSABRINA HECHTSYLVIE BERGERNATACHA MOULHARATFRANCIS COGEGERALD GUILLAUMETVERONIQUE LECLERCSAID YOUSPHILIPPE DELAGRANGE, "Old and New Inhibitors of Quinone Reductase 2", Chemico-Biological Interactions, (20100000), vol. 186.2, doi:doi:10.1016/j.cbi.2010.04.006, pages 103 - 09, XP027075099 DOI: http://dx.doi.org/10.1016/j.cbi.2010.04.006 | - GRAVES, P. R.J. J. KWIEKP. FADDENR. RAYK. HARDEMANA. M. COLEYM. FOLEYT. A. HAYSTEAD, "Discovery of Novel Targets of Quinoline Drugs in the Human Purine Binding Proteome", Mol Pharmacol, (20020000), vol. 62, doi:doi:10.1124/mol.62.6.1364, pages 1364 - 372, XP002297994 DOI: http://dx.doi.org/10.1124/mol.62.6.1364 | - HARADASHOJICHIEKO FUJIIAKITO HAYASHINORIO OHKOSHI, "An Association between Idiopathic Parkinson's Disease and Polymorphisms of Phase II Detoxification Enzymes: Glutathione S-Transferase Ml and Quinone Oxidoreductase 1 and 2", Biochemical and Biophysical Research Communications, (20010000), vol. 288.4, pages 887 - 92 | - HARADASHOJIHIROKAZU TACHIKAWAYOICHI KAWANISHI, "A Possible Association between an Insertion/deletion Polymorphism of the NQ02 Gene and Schizophrenia", Psychiatric Genetics, (20030000), vol. 13.4, pages 205 - 09 | - HASHIMOTOTETSUYAMASAMI NAKAI, "Increased Hippocampal Quinone Reductase 2 in Alzheimer's Disease", Neuroscience Letters, (20110000), vol. 502.1, doi:doi:10.1016/j.neulet.2011.07.008, pages 10 - 12, XP028383453 DOI: http://dx.doi.org/10.1016/j.neulet.2011.07.008 | - ISKANDER, K., "Deficiency of NRH:Quinone Oxidoreductase 2 Increases Susceptibility to 7,12-Dimethylbenz(a)anthracene and Benzo(a)pyrene-Induced Skin Carcinogenesis", Cancer Research, (20040000), vol. 64.17, pages 5925 - 928 | - JAISWAL, A. K, "Human NAD(P)H:quinone Oxidoreductase2. Gene Structure, Activity, and Tissue-specific Expression", J Biol Chem, (19940000), vol. 269.20, pages 14502 - 4508 | - KWIEKJESSE J.TIMOTHY A.J. HAYSTEADJOHANNES RUDOLPH, "Kinetic Mechanism of Quinone Oxidoreductase 2 and Its Inhibition by the Antimalarial Quinolines", Biochemistry, (20040000), vol. 43.15, pages 4538 - 547 | - LOIS, C.E. J. HONGS. PEASEE. J. BROWND. BALTIMORE, "Germline Transmission and Tissue-specific Expression of Transgenes Delivered by Lentiviral Vectors", Science, (20020000), vol. 295.5556, doi:doi:10.1126/science.1067081, pages 868 - 72, XP002288582 DOI: http://dx.doi.org/10.1126/science.1067081 | - LONGDELWIN J.ANIL K. JAISWAL, "NRH:quinone Oxidoreductase2 (NQ02)", Chemico-Biological Interactions, (20000000), vol. 129.1-2, pages 99 - 112 | - MAILLIET, F.G. FERRYF. VELLAK. THIAMP. DELAGRANGEJ. A. BOUTIN, "Organs from Mice Deleted for NRH:quinone Oxidoreductase 2 Are Deprived of the Melatonin Binding Site MT3", FEBS Lett, (20040000), vol. 578, doi:doi:10.1016/j.febslet.2004.10.083, pages 116 - 20, XP004879143 DOI: http://dx.doi.org/10.1016/j.febslet.2004.10.083 | - MAILLIET, F.G. FERRYF. VELLAS. BERGERF. COGEP. CHOMARATC. MALLETS. P. GUENING. GUILLAUMETM. C. VIAUD-MASSUARD, "Characterization of the Melatoninergic MT3 Binding Site on the NRH:quinone Oxidoreductase 2 Enzyme", Biochem Pharmacol, (20050000), vol. 71, no. 1-2, doi:doi:10.1016/j.bcp.2005.09.030, pages 74 - 88, XP005191199 DOI: http://dx.doi.org/10.1016/j.bcp.2005.09.030 | - ROSENBLUM, K.N. MEIRIY. DUDAI, "Taste Memory: The Role of Protein Synthesis in Gustatory Cortex", Behavioral and Neural Biology, (19930000), vol. 59.1, pages 49 - 56 | - ROSENBLUM, K.R. SCHULLN. MEIRIY. R. HADARIY. ZICKY. DUDAI, "Modulation of Protein Tyrosine Phosphorylation in Rat Insular Cortex after Conditioned Taste Aversion Training", Proceedings of the National Academy of Sciences, (19950000), vol. 92.4, pages 1157 - 161 | - VELLA, F.G. FERRYP. DELAGRANGEJ. BOUTIN, "NRH:quinone Reductase 2: An Enzyme of Surprises and Mysteries", Biochemical Pharmacology, (20050000), vol. 71.1-2, doi:doi:10.1016/j.bcp.2005.09.019, pages 1 - 12, XP005191191 DOI: http://dx.doi.org/10.1016/j.bcp.2005.09.019 | - WANG, W.A. JAISWAL, "Sp3 Repression of Polymorphic Human NRH:quinone Oxidoreductase 2 Gene Promoter", Free Radical Biology and Medicine, (20040000), vol. 37.8, doi:doi:10.1016/j.freeradbiomed.2004.06.042, pages 1231 - 243, XP004580149 DOI: http://dx.doi.org/10.1016/j.freeradbiomed.2004.06.042 | - VORHEES C.V.WILLIAMS M.T., "Morris water maze: procedures for assessing spatial and related forms of learning and memory", Nat Protoc., (20060000), vol. 1, no. 2, pages 848 - 58 |